Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Ipilimumab in Combination With Carboplatin and Paclitaxel in Patients With Unresectable Stage III or Stage IV Melanoma

NCT01676649 is registered in ClinicalTrials.gov with Jewish General Hospital as lead sponsor.

NCT NCT01676649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01676649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Ipilimumab in Combination With Carboplatin and Paclitaxel in Patients With Unresectable Stage III or Stage IV Melanoma
Lead sponsor
Jewish General Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2012
Completion date
May 31, 2026
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

untreated stage iii melanoma or stage iv melanoma